Drug Profile
Elosulfase alfa - BioMarin Pharmaceuticals
Alternative Names: BMN-110; GALNS; Recombinant N-acetylgalactosamine-6-sulfatase; rhGALNS; Vimizaim; VimizimLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Class Chondroitinsulfatases; Recombinant proteins
- Mechanism of Action GALNS protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mucopolysaccharidosis IV